US Cancer Mortality Fell 35% Since 1991

Improved survival rates have averted over 4.8 million deaths, though new research funding faces significant federal budget hurdles.

Updated on Oct. 5, 2026 in Cancer

Bold flat-color editorial illustration depicting a single glass laboratory vial in navy, cream, and deep red, representing medical research progress. — US cancer mortality has declined 35% since 1991, though future progress remains threatened by proposed federal funding cuts to the National Institutes of Health. AI Illustration. Upload story photo >

Live Poll

Should the federal government prioritize long-term medical research funding over proposed budget cuts?

Cancer mortality in the United States has declined by 35% since 1991, a shift that has prevented more than 4.8 million deaths. This progress stems from advancements in early detection, smoking cessation, and consistent government-funded research.

Why it matters

While overall survival rates reached 70% for patients diagnosed between 2015 and 2021, the trajectory of future care remains uncertain due to proposed federal budget cuts to the National Institutes of Health. Maintaining these gains depends on continued investment in both basic research and clinical innovation.

Five-year survival rates vary significantly, ranging from over 95% for thyroid, prostate, and skin cancers to less than 22% for liver, esophageal, and pancreatic malignancies. The FDA approved 11 new anticancer therapeutics between July 2025 and June 2026.

The players

National Institutes of Health

This is the primary federal agency responsible for biomedical and public health research in the United States.

National Comprehensive Cancer Network

This organization is a non-profit alliance of cancer centers dedicated to improving the quality and effectiveness of care.

President Donald Trump

He is the current President of the United States whose administration has proposed significant budget cuts to the NIH.

The details

Progress in treatment includes the drug Rasonque, which extends the lives of advanced pancreatic cancer patients by a median of 13.2 months. Despite these medical advancements, gaps remain, as fewer than 62% of lung cancer patients receive treatments that align with National Comprehensive Cancer Network guidelines.

The decline in cancer death rates began in 1991.
The 70% survival rate reflects patients diagnosed between 2015 and 2021.
The administration proposed cuts to the NIH and NCI in 2025.
Eleven new anticancer therapeutics were approved between July 2025 and June 2026.
The White House fiscal year 2027 budget proposes a 12% NIH budget cut.

Health Landscape

The fiscal year 2027 federal budget proposal introduces a major shift that threatens to interrupt the long-term momentum of national cancer research programs. This development contrasts with decades of consistent investment that enabled the 35% decline in mortality since the early 1990s.

Patients may face changes in access to the latest clinical trials or therapeutic innovations if federal research funding is reduced. Additionally, the statistic showing that 38% of lung cancer patients do not receive guideline-recommended care highlights the need for patients to verify treatment plans with their specialists.

The takeaway

Advancements in cancer care have significantly improved outcomes, yet access to recommended treatments remains inconsistent across patient populations. Future progress depends heavily on balancing clinical research incentives with the stability of federal funding.

What happens next

Congress will determine the final allocation for the fiscal year 2027 budget, which will dictate the funding levels for the National Institutes of Health and associated cancer research programs.